Abstract 771P
Background
Endometrial carcinosarcoma is an aggressive variant of high-grade endometrial carcinoma, whose genomic landscape is poorly studied due to the low disease prevalence and the lack of known druggable molecular drivers. In this study, we explored the genomic profiles of this tumor to assess new targeted therapy and immunotherapy options for this uncommon and challenging disease.
Methods
We retrospectively analyzed 2,177 cases of endometrial carcinosarcoma from the Foundation Medicine database containing results from comprehensive genomic profiling (CGP) performed by next generation sequencing, to detect genomic alterations (GA), microsatellite instability (MSI), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH,) as a surrogate for homologous recombination deficiency (HRD). PD-L1 was evaluated using DAKO 22C3.
Results
The median age in the cohort was 67y (interquartile range: 61-72y). TP53 was the most common GA, found in 83.7% of cases. Additionally, samples harbored GAs in PIK3CA (34.2%), PTEN (23.5%), KRAS (16.0%), ARID1A (14.8%) ERBB2 (8.5%), BRCA2 (2.7%) and BRCA1 (2.0%). Immune checkpoint biomarkers were also prevalent; 171/2177 (7.9%) of assessable samples were TMB-high (≥10 mutations/megabase), 141/2170 (6.5%) were MSI-high, 795/1382 (30.7%) had PD-L1 positivity (TPS≥1%). HRD (gLOH≥16%) was observed in 351/1727 (20.3%) cases. A co-occurrence analysis revealed unique molecular subsets. TP53 was mutually exclusive with GAs in PTEN and ARID1A (OR = 0.2, p<1E-4). PTEN and ARID1A were highly co-occurrent (OR = 9.2, p<1E-4) and strongly overlapped the MSI-High subset (OR>40, p<1E-4). ERBB2 GAs, while co-occurrent with TP53 (OR = 2.2, p = 0.01), showed mutually exclusivity with PTEN (OR 0.4, p<1E-4) and TMB-high status (OR 0.3, p = 0.02).
Conclusions
To our knowledge, this is the largest reported series of endometrial carcinosarcoma, which could open new avenues for personalized approaches based on the identified targets including PIK3CA, HRD/gLOH, MSI, TMB, ERBB2 and ARID1A.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ugo De Giorgi.
Funding
Has not received any funding.
Disclosure
U.F.F. De Giorgi: Financial Interests, Personal, Advisory Board: Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Novartis, EISAI, Janssen; Financial Interests, Personal, Invited Speaker: Roche, BMS, Clovis Oncology, AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca, Sanofi, Roche. Z. Kuang, N.A. Danziger, J.A. Moore, D.I. Lin, E.S. Sokol, S. Sivakumar: Financial Interests, Personal, Stocks/Shares: Roche; Financial Interests, Personal, Full or part-time Employment: Foundation Medicine, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11